Retreatment with PARPi following stem cell transplant in a patient with recurrent ovarian cancer and myelodysplastic syndrome

Retreatment with PARPi following stem cell transplant in a patient with recurrent ovarian cancer and myelodysplastic syndrome

Objective: As the use of poly(adenosine diphosphate–ribose) polymerase inhibitors (PARPi) increases in the management of advanced ovarian cancer, therapy-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) may be observed more frequently. Strategies for management of this unique...

Full description

Saved in:
Bibliographic Details
Main Authors: Shilpa Mokshagundam, Mrinal M. Patnaik, Luigi A. DeVitis, Simrit K. Warring, Megan E. Grudem, Matthew S. Block
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Gynecologic Oncology Reports
Subjects:
PARP inhibitor
Myelodysplastic syndrome
Clonal hematopoiesis
Stem cell transplantation
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578925001316
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2352578925001316

Similar Items